Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma

Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose. However, due to a lack of tumor-specific targeting, the concentration of the drug in tumor tissue cannot be permanently maintained at a level that i...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaolong Tang (Author), Longzhou Chen (Author), Amin Li (Author), Shiyu Cai (Author), Yinci Zhang (Author), Xueke Liu (Author), Zhenyou Jiang (Author), Xinkuang Liu (Author), Yong Liang (Author), Dong Ma (Author)
Format: Book
Published: Taylor & Francis Group, 2018-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available